Abstract
Structural modifications of the initial lead, 3-aminochroman (4), led to the identification of a novel series of pyridyl-fused amino chroman derivatives (5-8) and the structural isomers (9-12). The compounds described were evaluated for dual 5-HT transporter inhibitory and 5-HT(1A) receptor activities. The design strategy, synthesis, and in vitro biological characterization for these novel compounds are described.
MeSH terms
-
Animals
-
Chromans / chemistry*
-
Chromans / pharmacology*
-
Humans
-
Rats
-
Receptor, Serotonin, 5-HT1A / drug effects*
-
Receptor, Serotonin, 5-HT1A / metabolism
-
Selective Serotonin Reuptake Inhibitors / chemical synthesis
-
Selective Serotonin Reuptake Inhibitors / chemistry*
-
Selective Serotonin Reuptake Inhibitors / pharmacology*
-
Serotonin Plasma Membrane Transport Proteins / drug effects*
-
Serotonin Plasma Membrane Transport Proteins / metabolism
Substances
-
Chromans
-
Serotonin Plasma Membrane Transport Proteins
-
Serotonin Uptake Inhibitors
-
Receptor, Serotonin, 5-HT1A